Merck & Company (MRK) 56.68 $MRK
China Rule Change Further Opens Yuan To World Markets
at Investor's Business Daily - Mon Apr 28, 5:31PM CDT
Big purses started spilling open around the globe in the past week. GlaxoSmithKline (GSK), Novartis (NVS) and Eli Lilly (LLY) announced a series of business swaps valued at $19.9 billion. AstraZeneca (AZN) straight-armed a $98 billion offer from...
Merck & Co., Inc. Earnings: Is Growth Around the Corner?
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
On Tuesday, Merck will release its quarterly report, and investors have sent the stock soaring to multiyear highs recently. Even though Merck's revenue and earnings aren't likely to grow from year-ago levels, Merck is showing promise in its...
Will Merck (MRK) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 3:35PM CDT
Merck (MRK) has an earnings ESP of -1.27% with Zacks Rank #3 (Hold).
Why Merck Will Move the Dow Tomorrow
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 28, 3:30PM CDT
The Dow Jones Industrials climbed 87 points on Monday, as investors were relieved not to have seen some of their immediate geopolitical fears pan out over the weekend. Part of the excitement in today's market action came from Dow component Pfizer...
One Put, One Call Option To Know About For Merck & Co.
at The Street - Mon Apr 28, 11:06AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the...
Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump
at Investor's Business Daily - Mon Apr 28, 10:39AM CDT
Pfizer (PFE) says it is trying to acquire fellow big pharma AstraZeneca, confirming an anonymously sourced report from last week. Pfizer stock was up 4.5% and AstraZeneca 15% in morning trading on the stock market today. Pfizer bid for AstraZeneca on...
How to Trade 3D Systems, eBay, Panera Bread Earnings Reports Today
at The Street - Mon Apr 28, 8:00AM CDT
Yamana Gold, Cummins, Goodyear Tire, Marriott, Merck and TRW Automotive also report quarterly results on Tuesday.
Practice Fusion Teams with Merck on Population Health Management Initiative
PR Newswire - Mon Apr 28, 7:30AM CDT
Practice Fusion, the country's largest physician-patient community, today launched its Population Health Management offering in collaboration with Merck (NYSE:MRK), a global healthcare leader committed to increasing access to health care for patients through far-reaching policies, programs and partnerships.
Merck to Hold Investor Briefing at Boston Research Facility
Business Wire - Mon Apr 28, 6:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold an Investor Briefing on Tuesday, May 6, 2014 starting at 9:00 a.m. EDT at its research facility in Boston, MA. During the event, members of Merck's senior management will detail the company's research strategy, showcase candidates from the research and development pipeline and provide a business update.
Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies
Business Wire - Mon Apr 28, 6:01AM CDT
Agenus Inc. (NASDAQ: AGEN) announced today that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer. Under the terms of the agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the 4-Antibody Retrocyte Display(R) platform. Merck will be responsible for clinical development and commercialization of candidates generated under the collaboration.
Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Marketwire - Mon Apr 28, 5:30AM CDT
Merck KGaA (FRANKFURT: MRK)
Global Rosacea Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwn2d4/rosacea) has announced the addition of the "Global Rosacea Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rosacea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Rosacea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rosacea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Allergan, Inc. - Merck & Co., Inc. - Novartis AG - Amorepacific Corporation - Galderma S.A. - Paratek Pharmaceuticals, Inc. - Celgene Corporation - Paloma Pharmaceuticals, Inc. - Foamix Ltd. - Gene Signal International SA - Cutanea Life Sciences - Sol-Gel Technologies Ltd. - Signum Biosciences, Inc. - Advancell - Delenex Therapeutics AG - TWi Pharmaceuticals, Inc. - Dermira Inc. Drug Profiles - omiganan pentahydrochloride - ivermectin - sirolimus - apremilast - DRM-02 - (betamethasone calcipotriene) - oxymetazoline hydrochloride - benzoyl peroxide - DER-45EV - PAC-14028 - PDI-320 - AC-701 - aganirsen - cromolyn sodium - laropiprant - sarecycline hydrochloride - SIG-990 - DLX-1008 - ANs-29 - GM-1111 - SIG-989 - SIG-1191 - SIG-1192 - P-529 - minocycline Gel For more information visit http://www.researchandmarkets.com/research/mwn2d4/rosacea
Research and Markets: PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies
Business Wire - Mon Apr 28, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wlpkbs/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players" report to their offering.
Global Metastatic Ovarian Cancer Clinical Trials Report 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4dxh6f/metastatic) has announced the addition of the "Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Ovarian Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - F. Hoffmann-La Roche Ltd. - MolMed S.p.A. - Isis Pharmaceuticals, Inc. - E. Merck KG - Daiichi Sankyo Company, Limited - AbbVie Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - California Stem Cell, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - NCIC Clinical Trials Group - University of Washington - The University of Texas Health Science Center at San Antonio - Rutgers, The State University of New Jersey - European Organization for Research and Treatment of Cancer - Albert Einstein College of Medicine of Yeshiva University - Karolinska Institutet - Weill Cornell Medical College For more information visit http://www.researchandmarkets.com/research/4dxh6f/metastatic
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
Global Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2014 - Analysis of 26 Companies & 57 Drug Profiles
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b58mx2/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Vical Incorporated - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - Novartis AG - Astellas Pharma Inc. - 4SC AG - Bionor Pharma ASA - Altor BioScience Corporation - Phoenix Biotechnology, Inc. - Cell Medica Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Microbiotix, Inc. - 4-Antibody AG - VBI Vaccines - AIMM Therapeutics B.V. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - Spider Biotech S.r.l. - INAGEN ApS - Applied Immune Technologies Ltd - Redbiotec AG - Kadmon Corporation, LLC - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - brincidofovir - ASP-0113 - Cytovir CMV - maribavir - TCN-202 - ASP-0113 - Donor-Derived CMV-pp65 Peptide-Specific T Cells - letermovir - RG-7667 - Multi-Virus Specific T Cells - CMV pp65 Specific T Cells - T-Cell Immunotherapy - CMV Streptacells - Autologous T-Cell Therapy - AVX-601 - HCMV Specific CTL - CMV Specific CTL - Cytomegalovirus Vaccine - CMV Specific T Cell Donor Lymphocyte - Multi-Virus Cytotoxic T Lymphocytes - Small Molecule 1 For Human Cytomegalovirus Infection - Small Molecule 2 For Human Cytomegalovirus Infection - CMV TCR-001 - CMV-MVA Triplex Vaccine - V-160 - CyMVectin - Antiviral TCR-Ck - Antiviral TCR-Ig - 4Ab-028 - VPM-2001 For more information visit http://www.researchandmarkets.com/research/b5...egalovirus
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
Global Candidiasis Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr2b6p/candidiasis) has announced the addition of the "Global Candidiasis Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - Sequella, Inc. - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - Novartis AG - Eisai Co., Ltd. - iCo Therapeutics Inc. - Almirall, S.A. - Basilea Pharmaceutica AG - Pacgen Life Science Corporation - NovaDigm Therapeutics, Inc. - Cellceutix Corporation - Aureogen Biosciences, Inc. - Sealife PHARMA GMBH - Panacela Labs, Inc. - Biomar Microbial Technologies Drug Profiles - posaconazole - isavuconazonium - PAC-113 - LAS-41003 - NDV-3 Vaccine - SQ-109 - PMX-30016 - amphotericin B - E-1210 - SLP-0901 - D11-2040 - Xenomycin - AUGC-15 - Compound-18545 - Compound-9403 - PMX-1502 - PMX-519 - Candida Vaccine - PMX-1408 - E-1211 - SLP-1002 - SLP-0907 - Drugs for Fungal Infections - Small Molecules for Candidiasis - Compound-14844 - Program For Women Health - PMX-70004 - PMX-1570 - PMX-1576 - PMX-1591 - PMX-1625 - Small Molecules for Aspergillosis and Candidiasis - Small Molecules for Candidiasis - Drugs for Fungal Infections - PAC-113 For more information visit http://www.researchandmarkets.com/research/xr...andidiasis
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies
M2 - Mon Apr 28, 3:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8gl3q/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players" report to their offering. PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the key companies shaping and driving the global prophylactic hepatitis B virus vaccines market. The report provides insight into the competitive prophylactic hepatitis B virus vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for prophylactic hepatitis B virus vaccines - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of prophylactic hepatitis B virus vaccines sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 3.1 Global Markets 3.1.1 Forecast 3.1.2 Drivers and Barriers - Global Issues 4 Current and Future Players 4.1 Overview 4.2 Trends in Corporate Strategy 4.3 Company Profiles 4.3.1 GSK 4.3.2 Merck 4.3.3 Sanofi 4.3.4 Kaketsuken 4.3.5 Dynavax Technologies 5 Appendix Companies Mentioned - GSK - Merck - Sanofi - Kaketsuken - Dynavax Technologies For more information visit http://www.researchandmarkets.com/research/c8...harmapoint
China Rule Change Further Opens Yuan To World Markets
at Investor's Business Daily - Mon Apr 28, 5:31PM CDT
Big purses started spilling open around the globe in the past week. GlaxoSmithKline (GSK), Novartis (NVS) and Eli Lilly (LLY) announced a series of business swaps valued at $19.9 billion. AstraZeneca (AZN) straight-armed a $98 billion offer from...
Merck & Co., Inc. Earnings: Is Growth Around the Corner?
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
On Tuesday, Merck will release its quarterly report, and investors have sent the stock soaring to multiyear highs recently. Even though Merck's revenue and earnings aren't likely to grow from year-ago levels, Merck is showing promise in its...
Will Merck (MRK) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 3:35PM CDT
Merck (MRK) has an earnings ESP of -1.27% with Zacks Rank #3 (Hold).
Why Merck Will Move the Dow Tomorrow
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 28, 3:30PM CDT
The Dow Jones Industrials climbed 87 points on Monday, as investors were relieved not to have seen some of their immediate geopolitical fears pan out over the weekend. Part of the excitement in today's market action came from Dow component Pfizer...
One Put, One Call Option To Know About For Merck & Co.
at The Street - Mon Apr 28, 11:06AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the...
Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump
at Investor's Business Daily - Mon Apr 28, 10:39AM CDT
Pfizer (PFE) says it is trying to acquire fellow big pharma AstraZeneca, confirming an anonymously sourced report from last week. Pfizer stock was up 4.5% and AstraZeneca 15% in morning trading on the stock market today. Pfizer bid for AstraZeneca on...
How to Trade 3D Systems, eBay, Panera Bread Earnings Reports Today
at The Street - Mon Apr 28, 8:00AM CDT
Yamana Gold, Cummins, Goodyear Tire, Marriott, Merck and TRW Automotive also report quarterly results on Tuesday.
Practice Fusion Teams with Merck on Population Health Management Initiative
PR Newswire - Mon Apr 28, 7:30AM CDT
Practice Fusion, the country's largest physician-patient community, today launched its Population Health Management offering in collaboration with Merck (NYSE:MRK), a global healthcare leader committed to increasing access to health care for patients through far-reaching policies, programs and partnerships.
Merck to Hold Investor Briefing at Boston Research Facility
Business Wire - Mon Apr 28, 6:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold an Investor Briefing on Tuesday, May 6, 2014 starting at 9:00 a.m. EDT at its research facility in Boston, MA. During the event, members of Merck's senior management will detail the company's research strategy, showcase candidates from the research and development pipeline and provide a business update.
Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies
Business Wire - Mon Apr 28, 6:01AM CDT
Agenus Inc. (NASDAQ: AGEN) announced today that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer. Under the terms of the agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the 4-Antibody Retrocyte Display(R) platform. Merck will be responsible for clinical development and commercialization of candidates generated under the collaboration.
Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Marketwire - Mon Apr 28, 5:30AM CDT
Merck KGaA (FRANKFURT: MRK)
Global Rosacea Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwn2d4/rosacea) has announced the addition of the "Global Rosacea Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rosacea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Rosacea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rosacea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Allergan, Inc. - Merck & Co., Inc. - Novartis AG - Amorepacific Corporation - Galderma S.A. - Paratek Pharmaceuticals, Inc. - Celgene Corporation - Paloma Pharmaceuticals, Inc. - Foamix Ltd. - Gene Signal International SA - Cutanea Life Sciences - Sol-Gel Technologies Ltd. - Signum Biosciences, Inc. - Advancell - Delenex Therapeutics AG - TWi Pharmaceuticals, Inc. - Dermira Inc. Drug Profiles - omiganan pentahydrochloride - ivermectin - sirolimus - apremilast - DRM-02 - (betamethasone calcipotriene) - oxymetazoline hydrochloride - benzoyl peroxide - DER-45EV - PAC-14028 - PDI-320 - AC-701 - aganirsen - cromolyn sodium - laropiprant - sarecycline hydrochloride - SIG-990 - DLX-1008 - ANs-29 - GM-1111 - SIG-989 - SIG-1191 - SIG-1192 - P-529 - minocycline Gel For more information visit http://www.researchandmarkets.com/research/mwn2d4/rosacea
Research and Markets: PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies
Business Wire - Mon Apr 28, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wlpkbs/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players" report to their offering.
Global Metastatic Ovarian Cancer Clinical Trials Report 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4dxh6f/metastatic) has announced the addition of the "Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Ovarian Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - F. Hoffmann-La Roche Ltd. - MolMed S.p.A. - Isis Pharmaceuticals, Inc. - E. Merck KG - Daiichi Sankyo Company, Limited - AbbVie Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - California Stem Cell, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - NCIC Clinical Trials Group - University of Washington - The University of Texas Health Science Center at San Antonio - Rutgers, The State University of New Jersey - European Organization for Research and Treatment of Cancer - Albert Einstein College of Medicine of Yeshiva University - Karolinska Institutet - Weill Cornell Medical College For more information visit http://www.researchandmarkets.com/research/4dxh6f/metastatic
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
Global Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2014 - Analysis of 26 Companies & 57 Drug Profiles
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b58mx2/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Vical Incorporated - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - Novartis AG - Astellas Pharma Inc. - 4SC AG - Bionor Pharma ASA - Altor BioScience Corporation - Phoenix Biotechnology, Inc. - Cell Medica Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Microbiotix, Inc. - 4-Antibody AG - VBI Vaccines - AIMM Therapeutics B.V. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - Spider Biotech S.r.l. - INAGEN ApS - Applied Immune Technologies Ltd - Redbiotec AG - Kadmon Corporation, LLC - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - brincidofovir - ASP-0113 - Cytovir CMV - maribavir - TCN-202 - ASP-0113 - Donor-Derived CMV-pp65 Peptide-Specific T Cells - letermovir - RG-7667 - Multi-Virus Specific T Cells - CMV pp65 Specific T Cells - T-Cell Immunotherapy - CMV Streptacells - Autologous T-Cell Therapy - AVX-601 - HCMV Specific CTL - CMV Specific CTL - Cytomegalovirus Vaccine - CMV Specific T Cell Donor Lymphocyte - Multi-Virus Cytotoxic T Lymphocytes - Small Molecule 1 For Human Cytomegalovirus Infection - Small Molecule 2 For Human Cytomegalovirus Infection - CMV TCR-001 - CMV-MVA Triplex Vaccine - V-160 - CyMVectin - Antiviral TCR-Ck - Antiviral TCR-Ig - 4Ab-028 - VPM-2001 For more information visit http://www.researchandmarkets.com/research/b5...egalovirus
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
Global Candidiasis Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr2b6p/candidiasis) has announced the addition of the "Global Candidiasis Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - Sequella, Inc. - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - Novartis AG - Eisai Co., Ltd. - iCo Therapeutics Inc. - Almirall, S.A. - Basilea Pharmaceutica AG - Pacgen Life Science Corporation - NovaDigm Therapeutics, Inc. - Cellceutix Corporation - Aureogen Biosciences, Inc. - Sealife PHARMA GMBH - Panacela Labs, Inc. - Biomar Microbial Technologies Drug Profiles - posaconazole - isavuconazonium - PAC-113 - LAS-41003 - NDV-3 Vaccine - SQ-109 - PMX-30016 - amphotericin B - E-1210 - SLP-0901 - D11-2040 - Xenomycin - AUGC-15 - Compound-18545 - Compound-9403 - PMX-1502 - PMX-519 - Candida Vaccine - PMX-1408 - E-1211 - SLP-1002 - SLP-0907 - Drugs for Fungal Infections - Small Molecules for Candidiasis - Compound-14844 - Program For Women Health - PMX-70004 - PMX-1570 - PMX-1576 - PMX-1591 - PMX-1625 - Small Molecules for Aspergillosis and Candidiasis - Small Molecules for Candidiasis - Drugs for Fungal Infections - PAC-113 For more information visit http://www.researchandmarkets.com/research/xr...andidiasis
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies
M2 - Mon Apr 28, 3:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8gl3q/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players" report to their offering. PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the key companies shaping and driving the global prophylactic hepatitis B virus vaccines market. The report provides insight into the competitive prophylactic hepatitis B virus vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for prophylactic hepatitis B virus vaccines - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of prophylactic hepatitis B virus vaccines sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 3.1 Global Markets 3.1.1 Forecast 3.1.2 Drivers and Barriers - Global Issues 4 Current and Future Players 4.1 Overview 4.2 Trends in Corporate Strategy 4.3 Company Profiles 4.3.1 GSK 4.3.2 Merck 4.3.3 Sanofi 4.3.4 Kaketsuken 4.3.5 Dynavax Technologies 5 Appendix Companies Mentioned - GSK - Merck - Sanofi - Kaketsuken - Dynavax Technologies For more information visit http://www.researchandmarkets.com/research/c8...harmapoint
